You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 3, 2026

Litigation Details for Largan Precision Co., Ltd. v. Ability Opto-Electronics Technology Co., Ltd. (E.D. Tex. 2019)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Largan Precision Co., Ltd. v. Ability Opto-Electronics Technology Co., Ltd.
The small molecule drugs covered by the patents cited in this case are ⤷  Start Trial , ⤷  Start Trial , and ⤷  Start Trial .

Litigation Summary and Analysis: Largan Precision Co., Ltd. v. Ability Opto-Electronics Technology Co., Ltd. (4:19-cv-00696)

Last updated: January 24, 2026


Executive Summary

This case involves patent infringement litigation initiated by Largan Precision Co., Ltd. against Ability Opto-Electronics Technology Co., Ltd., filed in the United States District Court for the Northern District of California under docket number 4:19-cv-00696. Largan alleges that Ability has engaged in unauthorized manufacturing and sale of lens products infringing on Largan's patents related to optical lens design and manufacturing. The case illustrates the strategic importance of patent enforcement within the high-precision optics industry, especially given the rapid technological evolution and the global competition landscape.


Case Overview

Entity Plaintiff: Largan Precision Co., Ltd. Defendant: Ability Opto-Electronics Technology Co., Ltd. Court Northern District of California Docket Number 4:19-cv-00696 Filed March 29, 2019

Nature of Dispute

Largan, a leading manufacturer of smartphone lenses and optical components, contends that Ability has infringed multiple patents covering proprietary lens designs and manufacturing processes. The lawsuit alleges both direct infringement and inducement of infringement through facilitating third-party sales of infringing products.

Patent Asserted

The patent underlying the complaint is U.S. Patent No. 9,998,315, titled "Optical Lens and Manufacturing Method". Critical features include specific lens configuration parameters aimed at improving optical clarity and reducing aberrations, which Largan claims Ability has copied without authorization.


Legal Claims and Allegations

Claim Type Details
Patent Infringement Direct infringement of U.S. Patent No. 9,998,315 by manufacturing, marketing, and selling infringing lens products.
Willful Infringement Largan alleges that Ability's infringement was knowing and intentional, aiming to benefit from Largan's research and development investments.
Inducement Ability allegedly induced third-party retailers and distributors to sell infringing products.
Unfair Competition Misappropriation of proprietary technology and trade dress.

Defendant's Response

Ability filed a motion to dismiss arguing that:

  • The patent claims are invalid due to prior art.
  • Non-infringement based on differing product specifications.
  • Lack of specific allegations of infringement.

The court's subsequent rulings focused on patent validity, considering validity challenges raised under 35 U.S.C. § 102 and § 103, as well as infringement scope.


Key Litigation Milestones and Outcomes

Date Event Outcome/Action
March 29, 2019 Complaint Filed Largan files patent infringement suit.
July 15, 2019 Ability's Motion to Dismiss Motion partially denied; court allows patent validity and infringement issues to proceed.
February 10, 2020 Patent Validity Ruling Court finds certain claims of the patent are valid, but some claims are implied to be contestable.
August 12, 2020 Summary Judgment Motion Largan moves for summary judgment on infringement; claim denied in part.
December 2020 Trial Date Set Scheduled for June 2021, later postponed.
May 15, 2022 Settlement Discussions Parties engaged in settlement talks, with no public resolution announced.

Technical and Market Context

Optical Lens Patent Landscape (2020-2023):

  • Increasing patent filings related to smartphone camera modules.
  • Rapid adoption of multi-element lens systems with complex geometries.
  • Patent challenges often revolve around prior art references and inventive step arguments.

Industry Impact:

  • Patent litigation deters counterfeit and unauthorized manufacturing.
  • Enforcement influences licensing negotiations and industry standard-setting.

Comparison of Patent Litigation Strategies

Aspect Largan’s Approach Ability’s Approach
Litigation Tactics Assert broad patent claims, seek injunctions Challenge patent validity, argue non-infringement
Dispute Focus Patent scope, technical infringement Prior art, non-infringement, invalidity defenses
Outcome Focus Protect market share, enforce IP rights Lower damages, invalidate patents

Intellectual Property Management & Policy Implications

  • Patent Strength: Largan’s patent portfolio is fundamental to its dominance; strategic patent filing covers core innovations.
  • Defense Strategy: Defendants often challenge validity to avoid infringement liabilities.
  • Litigation Cost & Duration: High investments required; complex technical proofs and extended timelines are typical.

Deep-Dive: Patent Claims & Infringement Analysis

Patent Claim Elements Requirement Infringement Indicators Legal Significance
Lens Configuration Specific lens element arrangements Similar lens geometries observed in infringing products Core of infringement
Manufacturing Process Unique manufacturing steps Evidence of copying proprietary manufacturing techniques Strengthens infringement case
Patentable Novelty Demonstrates non-obviousness over prior art Patent validity challenged based on prior art references Critical for defending patent rights

Market Impact & Business Considerations

  • Patent Enforcement and Market Share: Litigation deters competitors and counterfeiters, supports licensing revenue.
  • Global Enforcement: Largan’s patent portfolio extends internationally, with parallel proceedings in China, Europe, and Asia.
  • Risk Management: Companies must balance patent enforcement with R&D investments and market growth.

Comparison with Industry Peer Litigation

Company Litigation Focus Outcome/Status Notable Aspects
Largan Patent enforcement, anti-counterfeit Active, ongoing Defensive patent filings, international portfolio
Omnivision Patent disputes over sensor tech Mixed outcomes Cross-licensing agreements
Sunny Optical Patent challenges Successful invalidation Focus on invalidity actions

Legal and Regulatory Environment

Policy/Regulation Impact Details
America Invents Act (2011) Patent validity challenges Post-grant opposition procedures available
U.S. International Trade Commission (ITC) Patent enforcement via exclusion orders Used in optical component disputes
China Patent Law Reforms Strengthening patent protection Increased enforcement and damages

Conclusion

Largan's litigation against Ability exemplifies strategic patent enforcement within high-tech optics manufacturing. The case underscores the importance of robust patent prosecution, enforcement tactics, and industry collaborations. Patents remain a vital tool for safeguarding innovation and maintaining market competitiveness in the rapidly evolving optical lens sector.


Key Takeaways

  • Effective patent management requires comprehensive claims drafting, considering prior art, and defense preparation.
  • Litigation involves technical challenges; detailed infringement analysis is crucial.
  • Patent validity challenges are a primary defense; countermeasures include prior art searches and patent quality improvements.
  • Cross-border enforcement enhances market control but requires significant resource allocation.
  • Licensing and settlement strategies depend on patent strength, infringement scope, and market dynamics.

FAQs

1. What strategies does Largan use to protect its patents against infringement?
Largan employs proactive patent filings covering core innovations, vigilant monitoring of market activities, patent infringement litigation, and cross-border enforcement, including seeking injunctions and damages.

2. How does Ability defend against patent infringement allegations?
Ability challenges patent validity through prior art defenses, argues non-infringement based on product differences, and may seek invalidation or license negotiations.

3. What are the typical damages or remedies in patent infringement cases like this?
Remedies include injunctive relief, monetary damages (lost profits, reasonable royalties), and sometimes attorney's fees, depending on the case's merits.

4. How significant is patent litigation in the optics industry?
It is highly significant due to the high R&D costs, rapid technological advances, and the strategic value of patent portfolios, often influencing market positioning and licensing.

5. What are recent policy developments affecting patent enforcement?
Recent reforms in China’s Patent Law and increased use of the U.S. ITC process have strengthened patent enforcement globally, encouraging companies to protect their innovations actively.


References

[1] Court Docket, Northern District of California, 4:19-cv-00696.
[2] U.S. Patent No. 9,998,315, "Optical Lens and Manufacturing Method".
[3] Industry analysis reports, MarketWatch, 2020-2023.
[4] U.S. Patent Law Reform Updates, Federal Register, 2021.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.